GlassScriptPhysician profile
Matthew L Carnes
NPI 1760572531
$6,219.62
in general payments reported to CMS, 2019-2025
37 companies · $993 in 2025
The $993 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $945 · 2020: $306 · 2021: $1,021 · 2022: $821 · 2023: $600 · 2024: $1,534 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,126.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,190.55 | 2019-2025 | Linzess, Viberzi, Creon |
| Wilson Cook Medical Incorporated | $541.14 | 2019 | |
| Janssen Biotech, INC. | $510.90 | 2019-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $407.88 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $385.04 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $325.65 | 2019-2024 | Xifaxan, Trulance, Relistor |
| Phathom Pharmaceuticals, INC. | $277.62 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $148.43 | 2024 | Rezdiffra |
| Braintree Laboratories, INC. | $114.36 | 2022-2025 | Suflave, Sutab |
| Celgene Corporation | $110.70 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $94.30 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $92.20 | 2020-2024 | |
| 3-D Matrix, INC. | $91.98 | 2024 | |
| Daiichi Sankyo INC. | $90.17 | 2019-2022 | |
| Erbe USA INC | $90.00 | 2024-2025 | Vio3 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $77.57 | 2019 | |
| Mahana Therapeutics, INC. | $72.97 | 2022 | |
| Pfizer INC. | $68.71 | 2019-2024 | |
| Lilly USA, LLC | $52.59 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $47.88 | 2021-2023 | Dificid |
| Regeneron Healthcare Solutions, INC. | $44.07 | 2022-2023 | Dupixent |
| Olympus America INC. | $40.04 | 2023 | Evis Exera III Gastrointestinal Videoscope, Evis Exera Lll Colonovideoscope, Endoclot Phs |
| Redhill Biopharma INC. | $39.81 | 2021-2022 | |
| Ardelyx, INC. | $36.19 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $36.19 | 2019-2021 | |
| Allergan, INC. | $30.69 | 2019-2020 | |
| Cook Medical LLC | $29.33 | 2023 | Hemospray |
| Heron Therapeutics, INC. | $21.44 | 2025 | Zynrelef |
| Aimmune Therapeutics, INC. | $20.57 | 2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $19.58 | 2021 | |
| Novo Nordisk INC | $19.54 | 2025 | Wegovy |
| Celltrion USA INC. | $19.19 | 2024 | Vegzelma |
| Mallinckrodt Hospital Products INC. | $17.59 | 2022 | |
| Boston Scientific Corporation | $15.78 | 2024 | Spyglass Discover |
| Capsovision, INC. | $14.51 | 2024 | Capsocam Plus |
| Shionogi INC | $12.38 | 2019 | |
| Ucb, INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Carnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.